Biomea fusion, inc. reports inducement grant under nasdaq listing rule 5635(c)(4)

Redwood city, calif., march 03, 2025 (globe newswire) -- biomea fusion, inc. (“biomea”) (nasdaq: bmea), a clinical-stage diabetes and obesity medicines company, today announced that on march 3, 2025, the compensation committee of biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the company's common stock. the shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the company on such vesting dates. the above-described award was made under biomea's 2023 inducement equity plan (the “plan”).
NDAQ Ratings Summary
NDAQ Quant Ranking